NO20064473L - Stabilised supersaturated solid solutions of steroidal drugs - Google Patents

Stabilised supersaturated solid solutions of steroidal drugs

Info

Publication number
NO20064473L
NO20064473L NO20064473A NO20064473A NO20064473L NO 20064473 L NO20064473 L NO 20064473L NO 20064473 A NO20064473 A NO 20064473A NO 20064473 A NO20064473 A NO 20064473A NO 20064473 L NO20064473 L NO 20064473L
Authority
NO
Norway
Prior art keywords
solid solutions
supersaturated solid
steroidal drugs
lipophilic
silica
Prior art date
Application number
NO20064473A
Other languages
English (en)
Norwegian (no)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064473(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20064473L publication Critical patent/NO20064473L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO20064473A 2004-03-10 2006-10-02 Stabilised supersaturated solid solutions of steroidal drugs NO20064473L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10
PCT/IB2005/000748 WO2005087199A2 (en) 2004-03-10 2005-03-10 Stabilised supersaturated solid solutions of steroidal drugs

Publications (1)

Publication Number Publication Date
NO20064473L true NO20064473L (no) 2006-10-10

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064473A NO20064473L (no) 2004-03-10 2006-10-02 Stabilised supersaturated solid solutions of steroidal drugs

Country Status (32)

Country Link
US (1) US8715735B2 (de)
EP (2) EP1765290B1 (de)
JP (1) JP5006185B2 (de)
KR (1) KR101210695B1 (de)
CN (1) CN1984644B (de)
AR (1) AR048500A1 (de)
AT (1) ATE442131T1 (de)
AU (1) AU2005221403B8 (de)
BR (1) BRPI0507342A (de)
CA (1) CA2558582C (de)
CR (1) CR8630A (de)
DE (1) DE602005016551D1 (de)
DK (1) DK1765290T3 (de)
EA (1) EA012746B1 (de)
EC (1) ECSP066902A (de)
ES (2) ES2332229T3 (de)
GT (1) GT200500045A (de)
HR (1) HRP20090614T1 (de)
IL (1) IL177894A0 (de)
MY (1) MY142989A (de)
NO (1) NO20064473L (de)
NZ (1) NZ549793A (de)
PA (1) PA8626101A1 (de)
PE (1) PE20060016A1 (de)
PL (1) PL1765290T3 (de)
PT (1) PT1765290E (de)
RS (1) RS51076B (de)
SI (1) SI1765290T1 (de)
SV (1) SV2005002044A (de)
TW (1) TWI345986B (de)
UY (1) UY28803A1 (de)
WO (1) WO2005087199A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CN101232869B (zh) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
CA2612380C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
JP2009536165A (ja) * 2006-05-10 2009-10-08 エボニック デグサ ゲーエムベーハー 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
RU2485949C2 (ru) * 2007-04-11 2013-06-27 Фармасьютикал Продакшнс Инк Таблетка мелатонина и способы изготовления и применения
NZ586666A (en) * 2008-02-13 2012-04-27 Bayer Schering Pharma Ag Estradiol-containing drug delivery system
CA2718255C (en) * 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
HRP20151357T1 (hr) 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
JP2012505253A (ja) * 2008-10-10 2012-03-01 テバ ウィメンズ ヘルス インコーポレイテッド 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法
EP2398461A1 (de) * 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulierung mit drospirenon zur subkutanen oder intramuskulären verabreichung
US9005608B2 (en) * 2009-03-24 2015-04-14 Adds Pharmaceuticals Llc Stabilized solubility-enhanced formulations for oral delivery
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
AU2015292915B2 (en) 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
BR112019016692B1 (pt) * 2017-02-14 2023-12-05 Dsm Ip Assets B.V Formulações estáveis em armazenamento e uso das mesmas
PL3582626T3 (pl) * 2017-02-14 2022-02-14 Dsm Ip Assets B.V. Formulacje dyspergowalne w wodzie
CN110013467B (zh) 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP7847966B2 (ja) * 2020-10-23 2026-04-20 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
ATE118178T1 (de) * 1990-11-29 1995-02-15 Faulding F H & Co Ltd Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern.
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
SI1214076T1 (en) * 1999-08-31 2004-06-30 Schering Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
ATE442147T1 (de) 2000-01-18 2009-09-15 Bayer Schering Pharma Ag Pharmazeutische zubereitung enthaltend drospirenon
EP1260225A1 (de) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
EE200400034A (et) * 2001-06-22 2004-06-15 Pfizer Products Inc. Amorfse ravimaine adsorbaatide farmatseutilised kompositsioonid
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
ES2338782T3 (es) 2002-09-05 2010-05-12 Pantarhei Bioscience B.V. Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados.
WO2004041289A1 (en) 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
WO2004073689A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
BRPI0508612A (pt) 2004-03-10 2007-08-14 Schering Aktiengellschaft composições compreendendo drospirenona dispersa molecularmente

Also Published As

Publication number Publication date
ES2390406T3 (es) 2012-11-12
EP2087883A1 (de) 2009-08-12
EP2087883B1 (de) 2012-07-25
GT200500045A (es) 2005-10-31
DK1765290T3 (da) 2009-11-02
AU2005221403B2 (en) 2009-12-10
JP5006185B2 (ja) 2012-08-22
PT1765290E (pt) 2009-11-23
ES2332229T3 (es) 2010-01-29
WO2005087199A3 (en) 2009-01-15
RS51076B (sr) 2010-10-31
IL177894A0 (en) 2006-12-31
TWI345986B (en) 2011-08-01
EA012746B1 (ru) 2009-12-30
DE602005016551D1 (de) 2009-10-22
CR8630A (es) 2007-06-06
ECSP066902A (es) 2006-12-20
CA2558582C (en) 2013-07-16
HRP20090614T1 (hr) 2009-12-31
AR048500A1 (es) 2006-05-03
AU2005221403A1 (en) 2005-09-22
CA2558582A1 (en) 2005-09-22
US8715735B2 (en) 2014-05-06
JP2007528389A (ja) 2007-10-11
CN1984644A (zh) 2007-06-20
AU2005221403B8 (en) 2010-01-07
KR20060132999A (ko) 2006-12-22
SI1765290T1 (sl) 2010-01-29
ATE442131T1 (de) 2009-09-15
UY28803A1 (es) 2005-10-31
KR101210695B1 (ko) 2012-12-11
EP1765290B1 (de) 2009-09-09
PE20060016A1 (es) 2006-02-16
WO2005087199A8 (en) 2007-03-29
PA8626101A1 (es) 2006-07-03
HK1103660A1 (en) 2007-12-28
CN1984644B (zh) 2010-12-08
EP1765290A2 (de) 2007-03-28
MY142989A (en) 2011-02-14
PL1765290T3 (pl) 2010-02-26
EA200601588A1 (ru) 2007-02-27
SV2005002044A (es) 2005-11-04
WO2005087199A2 (en) 2005-09-22
NZ549793A (en) 2010-06-25
BRPI0507342A (pt) 2007-07-03
US20050207990A1 (en) 2005-09-22
TW200600116A (en) 2006-01-01

Similar Documents

Publication Publication Date Title
NO20064473L (no) Stabilised supersaturated solid solutions of steroidal drugs
EA200601570A1 (ru) Композиции, содержащие молекулярно диспергированный дроспиренон
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0512177A (pt) formulação de liberação modificada de memantina
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
BRPI0717509A2 (pt) sistema de liberação controlada para aplicação nasal de neurotransmissores
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
ATE538797T1 (de) Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
Nicolazzo et al. Enhancing the buccal mucosal uptake and retention of triamcinolone acetonide
Shokri et al. Liquisolid technology: What it can do for NSAIDs delivery?
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
Kalava et al. Physicochemical characterization and dissolution properties of cinnarizine solid dispersions
UA87838C2 (ru) Стабилизированные перенасыщенные твердые растворы липофильных лекарствнных средств
CY1109564T1 (el) Σταθεροποιημενα υπερκορεσμενα στερεα λιποφιλων φαρμακων
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
MX2008001532A (es) Composicion farmaceutica que contiene indometacina y/o acemetacina.
Li et al. Cosolubilization of non-polar drugs in polysorbate 80 solutions
NO20065657L (no) Filmformet ostriol-inneholdende medikament for oral administrasjon
BRPI0518239A2 (pt) composiÇÕes farmacÊuticas espontaneamente dispersÍveis
TH75689A (th) ของแข็งชนิดอิ่มตัวยิ่งยวดที่ผ่านการทำให้เสถียรของยาชนิดลิโพฟิลิก
TW200609000A (en) Molecular dispersions of drospirenone
TH171506A (th) องค์ประกอบทางเภสัชกรรมขนาดยาต่ำ
BR112017021995A2 (pt) formulação farmacêutica compreendendo drogas de baixa fusão e altamente lipofílicas e método de melhora da dissolução

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application